NeurologyLive
1 FOLLOWERS
NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats. Our mission is to deliver quality and relevant information to healthcare professionals treating neurological diseases to help them achieve the best patient care possible.
NeurologyLive
6d ago
The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes ..read more
NeurologyLive
6d ago
The chief medical officer at Biohaven provided insight on its investigational spinocerebellar ataxia agent troriluzole, the advantages of the newly developed SCACOMS measure, and how the therapy stacks against natural history data. [WATCH TIME: 4 minutes ..read more
NeurologyLive
6d ago
Ravulizumab reduced NfL levels in cerebrospinal fluid and serum whereas eculizumab showed no change in NfL when compared with placebo ..read more
NeurologyLive
6d ago
The original approval for chorea associated with Huntington disease was based on the phase 3 KINECT-HD study, an 128-patient cohort trial in which valbenazine met its primary end point ..read more
NeurologyLive
6d ago
The original approval for chorea associated with Huntington disease was based on the phase 3 KINECT-HD study, an 128-patient cohort trial in which valbenazine met its primary end point ..read more
NeurologyLive
2w ago
Results showed consistent reductions in monthly migraine days over 48 weeks, with a favorable safety profile observed ..read more
NeurologyLive
2w ago
Over 2, phase 3 studies, brexpiprazole-treated patients demonstrated greater response rates across various levels on the Cohen-Mansfield Agitation Index and Clinical Impression Scale-Improvement assessment ..read more
NeurologyLive
2w ago
An analysis of a phase 3 trial of low sodium oxybate in patients with idiopathic hypersomnia identified a minimal clinically important difference in the visual analog scale for sleep inertia ..read more
NeurologyLive
2w ago
A phase 3b study showed that switching from intravenous C5 inhibitors to subcutaneous zilucoplan in patients with myasthenia gravis was associated with symptom improvement at 12 weeks ..read more